SmartCella Holding AB

Busy week at SmartCella amid the Swedish summer – just announced another key milestone: the collaboration with US based XyloCor Therapeutics, Inc. ! Their novel XC001 gene therapy for refractory angina will be delivered by our FDA-cleared Extroducer – a powerful combination of delivery system, drug therapy and promising patient outcome. Our journey of pioneering the future of targeted therapies has only just begun so stay tuned! Read more about the license agreement https://lnkd.in/dBN7HFys #Extroducer #celltherapy

We are excited to announce our first commercial partnership for the #Extroducer: the team at XyloCor Therapeutics, Inc. will be using the technology in their upcoming phase 2 trial for XC001, delivering adenoviral payload to the heart to treat #RefractoryAngina. The deal provides XyloCor with commercial rights, and amounts to approximately USD 130 million and mid-single digit royalties. https://lnkd.in/dGcnPBym

We sat down with business daily Dagens Industri in Sweden to discuss SmartCella, the EUR 50 million capital raise, and the potential of the microcatheter Extroducer. The picture featuring Christian Kinch holding the Extroducer in his hand gives an idea of its minute size. Note that the article is in Swedish: https://lnkd.in/ddiDYsvg #Extroducer #celltherapy

Hear, hear – with EUR 50 million in new capital, we will accelerate growth and commercialization for SmartCella! As stated by CEO Niklas Prager “This capital raise is a landmark event for us – and our journey has only just begun.” Big thanks to existing investors Fjärde AP-fonden, AMF Pension, and SEB-Stiftelsen, and new investors AstraZeneca, Handelsbanken Fonder and RoosGruppen AB. Read the entire press release here: https://lnkd.in/dTS7d9Bn #Extroducer #celltherapy

Less than a week to go until International Society for Stem Cell Research #ISSCR2024 in Hamburg, Germany. Please join our CTO, Ricardo Baptista for his presentations on July 11 and 12, respectively. #iPSCs #celltherapy #Extroducer

As induced pluripotent stem cells (#iPSCs) are becoming a more widely adopted source material for a large range of #CellTherapies and #RegenerativeMedicine, identifying suitable lines with the appropriate ethical consent is crucial. In this recent article in Cell & Gene Therapy Insights, our CTO Ricardo Baptista discusses the current challenges with iPSirius COO Stephen Sullivan, PhD, MBA, FRSM, and highlights comprehensive strategies for the path to the clinic. Well worth a read! https://lnkd.in/eEZkGCpP

SmartCella had quite the eventful week, which also marked the first week of our US subsidiary spending team time in our Stockholm HQ: 🙋♀️AGM and Board Meeting with our new Board members on Monday. 🏃🏽♂️➡️Charity race on Tuesday. 🫎Company summer party with “real” vikings on Wednesday. 🖇️A pre-mortem workshop with the Solutions business unit on Thursday. 🏟️And closed out by the Euro kick-off on Friday night. Here‘s to an exciting journey ahead of us!

On Monday, we held our 2024 Annual General Meeting and are excited to introduce our new board members: Anna Martling Claude Dartiguelongue and Regina Fritsche Danielson. A warm welcome aboard – we can’t wait to start working together and "shape the future of targeted medicine through innovation and solid clinical data with the ambition of making targeted medicine a reality for many." Read more: https://lnkd.in/dhD68a-t